Lilly-Vir's COVID-19 antibody combo reduces viral load in study

Antibody treatments from Eli Lilly and Vir Biotech reduced viral load in low-risk COVID-19 patients, results from a mid-stage trial showed on Monday.The trial is testing Lilly's bamlanivimab given in combination with Vir and partner GlaxoSmithKline's VIR-7831, the companies said